The Technical Analyst
Nurix Therapeutics, Inc. [NRIX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Nurix Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-7.96% $13.29
America/New_York / 19 apr 2024 @ 13:45
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 788.33 mill |
| EPS: | -2.66 |
| P/E: | -5.00 |
| Earnings Date: | Jul 11, 2024 |
| SharesOutstanding: | 59.32 mill |
| Avg Daily Volume: | 0.990 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.00 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.85x |
| Company: PE -5.00 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 12.18 - 14.41 ( +/- 8.40%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-16 | Van Houte Hans | Sell | 6 812 | Common Stock |
| 2024-02-13 | Van Houte Hans | Buy | 150 000 | Employee Stock Option (right to buy) |
| 2024-02-13 | Van Houte Hans | Buy | 45 000 | Restricted Stock Units |
| 2024-02-13 | Ring Christine | Buy | 150 000 | Employee Stock Option (right to buy) |
| 2024-02-13 | Ring Christine | Buy | 45 000 | Restricted Stock Units |
| INSIDER POWER |
|---|
| 91.86 |
| Last 100 transactions |
| Buy: 2 499 418 | Sell: 108 263 |
Forecast:
15:23 - $13.32
Live Trading Signals (every 1 min)
Forecast
1: 13:53 - $13.29
Forecast 2: 14:43 - $13.31
Forecast 3: 15:23 - $13.32
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $13.29 (-7.96% ) |
| Volume | 0.355 mill |
| Avg. Vol. | 0.990 mill |
| % of Avg. Vol | 35.89 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NRIX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $8.56 | N/A | Active |
|---|
NRIX
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Latest Press Releases
2024-04-16 18:21:00 - Press Release
Nurix Therapeutics Announces Closing Of Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
San francisco, april 16, 2024 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix) today announced the closing of its underwritten public offering of 11,916,667 shares of its common stock at a public offering price of $15.00 per share, which includes 1,750,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock. in addition, and in lieu of common stock, nurix sold to certain investors pre-funded warrants to purchase 1,500,100 shares of common stock at a purchase price of $14.999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant...
2024-04-11 23:38:00 - Press Release
Nurix Therapeutics Announces Pricing Of Upsized $175.0 Million Public Offering
San francisco, april 11, 2024 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix) today announced the pricing of its upsized underwritten public offering of 10,166,667 shares of its common stock at a price to the public of $15.00 per share. in addition, and in lieu of common stock, nurix is offering to certain investors pre-funded warrants to purchase up to an aggregate of 1,500,100 shares of common stock at a purchase price of $14.999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. the gross proceeds to nurix from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by nurix, are expected to be $175...
2024-04-11 16:00:00 - Press Release
Nurix Therapeutics Announces Proposed Public Offering
San francisco, april 11, 2024 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that it has commenced an underwritten public offering of $125 million of its common stock and, in lieu of common stock, in the case of certain investors, pre-funded warrants to purchase shares of its common stock. in addition, nurix intends to grant the underwriters a 30-day option to purchase additional shares of its common stock at the public offering price less underwriting discounts and commissions. all of the securities will be offered and sold by nurix...
2024-04-10 07:00:00 - Press Release
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results And Provides A Corporate Update
Extended the strategic collaboration with gilead sciences extended the strategic collaboration with sanofi to develop novel orally available targeted protein degrader of stat6 presented new case studies on nx-5948 demonstrating clinical responses in patients with cns lymphoma and cll with cns involvement announced that it is part of a team of experts selected as awardees in this year's cancer grand challenges san francisco, april 10, 2024 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today reported financial results for the first quarter ended february 29, 2024, and provided a corporate update...
2024-04-09 13:15:00 - Press Release
Nurix Therapeutics Reports First Clinical Evidence Of Cns Activity Of Nx-5948, A Brain-penetrant, Orally Available, Btk Degrader In Development For B Cell Malignancies
Presented new case studies demonstrating clinical responses in two patients with b cell malignancies, chronic lymphocytic leukemia (cll) and primary central nervous system lymphoma (pcnsl), each with central nervous system (cns) involvement
Latest News
2024-04-10 10:31:13 - Zacks Investment Research
Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study
Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.
2024-04-10 09:11:09 - Zacks Investment Research
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $0.75 per share a year ago.
2024-04-03 07:00:00 - GlobeNewsWire
Nurix Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO, April 03, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D, Ph.D., president and chief executive officer of Nurix, Hans van Houte, Nurix's chief financial officer, and Jason Kantor, Ph.D., Nurix's chief business officer, will participate in the following conferences in April:
2024-03-06 16:00:00 - GlobeNewsWire
Nurix Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO, March 06, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Hans van Houte, Nurix's chief financial officer, and Jason Kantor, Ph.D., Nurix's chief business officer will participate in the following conferences in March: Leerink Partners Global Biopharma Conference 2024 One-on-one meetings only: Tuesday, March 12, 2024 Barclays Global Healthcare Conference Fireside chat: Wednesday, March 13, 2024, from 4:05 – 4:30 p.m.
2024-02-23 07:21:13 - Zacks Investment Research
Nurix Therapeutics, Inc. (NRIX) Surges 5.1%: Is This an Indication of Further Gains?
Nurix Therapeutics, Inc. (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
2024-02-15 18:11:05 - Zacks Investment Research
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.87 per share a year ago.
2024-01-02 16:01:00 - GlobeNewsWire
Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present an overview of Nurix's achievements in 2023 and major goals for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 3:00 p.m. PT.
2023-12-04 16:01:00 - GlobeNewsWire
Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual Meeting
SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that it will host a live webcast to review clinical data from the Phase 1 clinical trials of its Bruton's tyrosine kinase (BTK) degrader programs, NX-5945 and NX-2127, which are being evaluated in patients with relapsed or refractory B cell malignancies, at 8:30 p.m. PST (11:30 p.m. EST) on Monday, December 11, 2023.
2023-10-26 07:31:35 - Zacks Investment Research
New Strong Buy Stocks for October 26th
GRPN, NRIX, RNLX, ABCL and SMAR have been added to the Zacks Rank #1 (Strong Buy) List on October 26, 2023.
2023-10-18 11:20:04 - Zacks Investment Research
Down -34.9% in 4 Weeks, Here's Why Nurix Therapeutics, Inc. (NRIX) Looks Ripe for a Turnaround
Nurix Therapeutics, Inc. (NRIX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.